Sanofi - ADR

SNY

$52.61

+4.1% last 12 months

Ken Fisher Holding value: $725 Million Steven Cohen Holding value: $26.3 Million Ken Griffin Holding value: $20.8 Million Jeremy Grantham Holding value: $0 Joel Greenblatt Holding value: $0 Mario Gabelli Holding value: $0 Tom Russo Holding value: $0 George Soros Holding value: $0 Prem Watsa Holding value: $0 Warren Buffett Holding value: $0

Market Cap

$130 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

52 Week Range

$36.91 - $56.20

The lowest and highest price in the last 52 weeks.

Price-Earnings Ratio

14.53x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

Dividends per Share

$1.74 (3.37%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Revenue & Earnings

Balance Sheet

Share Statistics

Compare to
Market
Industry
Market Cap The market value of the company. It's calculated by multiplying the share price by the number of outstanding shares. $130 Billion
Enterprise Value A measure of a company's total value. This includes market cap, cash, and debt. -
Dividend Yield Yearly payout to shareholders per share. The percentage indicates the payout in relation to the share price. $1.74 (3.37%)
1 Year Return Profit or loss of share price change plus dividend yield. +7.5%
52-Week High Highest share price in the last 52 weeks. $56.20
52-Week Low Lowest share price in the last 52 weeks. $36.91
Beta Beta indicates the volatility of a stock compared to the market. Higher beta means more volatile and thus potentially higher risk and return. 0.39
Outstanding Shares The number of shares the company has issued and are held by stockholders. 2.52 Billion
Avg 30 Day Volume The number of shares traded in the last 30 days. 1.71 Million

Valuation

Compare to
Market
Industry
P/E Ratio Ratio between share price and earnings per share. A low ratio could indicate that the stock is undervalued or investors aren't expecting high growth. A high ratio could indicate that the stock is overvalued or investors are expecting high growth. 14.53
PEG The ratio between the P/E ratio and the growth rate of the company's earnings per share in the last twelve months. A lower PEG could mean that a stock is undervalued. -
Earnings per Share Earnings divided by outstanding shares. Higher EPS indicates greater value. $3.57
Price to Sales Ratio Market cap divided by the revenue in the most recent year. -
Price to Book Ratio Price to Book Ratio is the Market cap divided by the Book value of the company -
Enterprise Value to Revenue Enterprise value divided by revenue -
Enterprise Value to EBIT Enterprise Value divided by EBIT -
Total Debt to Enterprise Value Total debt divided by enterprise value -
Debt to Equity A higher ratio indicates a higher risk. However, the ratio is difficult to compare between industries where common amounts of debt vary. -

Profitability

Compare to
Market
Industry
Revenue Revenue is the sum of all cash flow into the company. -
Gross Profit Gross profit is the profit after subtracting the costs of making and selling its products or the costs of providing its services. It indicates the efficiency of using their resources to produce goods or services. -
EBIT Earnings before tax and interest payments. -
Net Income Net Income is the profit after all expenses have been deducted from the total revenue. -
Profit Margin Net income divided by revenue of the last 4 quarters. It indicates the company's profitability. -
Quarterly Earnings Growth (YoY) The rate at which the company's net income has increased to the same quarter one year ago. -
Return on Equity Equity divided by market cap. -
Return on Assets Indicates a company's profitability in relation to its total assets. -
Return on Invested Capital Return on invested capital (ROIC) is net income after dividends divided by the sum of debt and equity. It shows how effective a company is at turning capital invested by shareholders and other debtholders into profits. -

Insider trades

No purchases

No sells

No purchases

No sells

No purchases

No sells

No purchases

No sells

Q2 2022 Q3 2022 Q4 2022 Q1 2023

About Sanofi - ADR

CEO: Paul Hudson

Industry: Pharmaceuticals: Major

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Similar stocks

Merck & Co Inc
Merck & Co Inc
Pfizer Inc.
Pfizer Inc.
Novartis AG - ADR
Novartis AG - ADR
GSK Plc - ADR
GSK Plc - ADR
Teva- Pharmaceutical Industries Ltd. - ADR
Teva- Pharmaceutical Industries Ltd. - ADR
Johnson & Johnson
Johnson & Johnson
Lilly(Eli) & Co
Lilly(Eli) & Co
Novo Nordisk - ADR
Novo Nordisk - ADR
Abbott Laboratories
Abbott Laboratories

News

Provention Bio: Sanofi Acquires Provention Bio With A 273% Premium (NASDAQ:PRVB)

Provention Bio: Sanofi Acquires Provention Bio With A 273% Premium (NASDAQ:PRVB)

Sanofi proposed to acquire Provention Bio for $2.9B in cash at a 273% premium over the previous closing price. See why we maintain PRVB stock''s buy rating.

Seeking Alpha Seeking Alpha, about 21 hours ago
Regeneron''s Asthma Drug Results Were ''Stellar.'' Analyst Sees a Sales Bonanza.

Regeneron''s Asthma Drug Results Were ''Stellar.'' Analyst Sees a Sales Bonanza.

The company and its partner Sanofi presented data from a trial of the drug as a treatment for chronic obstructive pulmonary disease.

Barron''s Barron''s, 3 days ago
Sanofi, Regeneron shares pop more than 6% after data shows asthma drug Dupixent may also treat COPD

Sanofi, Regeneron shares pop more than 6% after data shows asthma drug Dupixent may also treat COPD

Sanofi and Regeneron unveiled data on their jointly developed drug for a difficult-to-treat chronic lung disorder that analysts say "exceeded expectations."

CNBC CNBC, 3 days ago
Sanofi And Regeneron Say Phase 3 Study Of Dupixent To Treat COPD Meets Endpoints

Sanofi And Regeneron Say Phase 3 Study Of Dupixent To Treat COPD Meets Endpoints

PARIS (dpa-AFX) - Sanofi S.A. (SNYNF) and Regeneron Pharmaceuticals, Inc. (REGN) on Thursday said late-stage study of their Dupixent for the treatment of chr...

Finanz Nachrichten Finanz Nachrichten, 4 days ago
Never miss a trade
To improve your user experience we use cookies.